[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
作者信息
Fujita K, Murayama T, Sayama T
出版信息
Gan To Kagaku Ryoho. 1984 Nov;11(11):2438-41.
PMID:6497402
Abstract
Seven cases with pulmonary metastases from the urogenital tract were treated with VP-16 in either oral doses of 200 mg or intravenous doses of 100 mg for 5 days. Two of 4 cases with transitional cell cancer from the urinary bladder and a case with prostatic adenocarcinoma responded to the treatment. Another 2 cases with adenocarcinoma arising from the kidney showed no response. Leucopenia, thrombocytopenia and alopecia were outstanding side effect.
摘要
相似文献
1
[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Gan To Kagaku Ryoho. 1984 Nov;11(11):2438-41.
2
[Effect of etoposide for urogenital tumors].
Gan To Kagaku Ryoho. 1985 Jun;12(6):1267-71.
3
[Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho. 1985 Jul;31(8):944-52.
4
[A phase II study of NK171 (etoposide)].
Gan To Kagaku Ryoho. 1985 Oct;12(10):2011-7.
5
[Intra-arterial infusion of antineoplastic agents in the treatment of urogenital cancer].[动脉内输注抗肿瘤药物治疗泌尿生殖系统癌症]
Gan To Kagaku Ryoho. 1982 Mar;9(3):415-20.
6
[A phase II study of oral VP-16 in primary lung cancer].
Gan To Kagaku Ryoho. 1985 Sep;12(9):1801-7.
7
Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.口服依托泊苷（VP - 16 - 213）治疗膀胱移行细胞癌：一项II期研究。
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):703-4.
8
[Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Gan To Kagaku Ryoho. 1986 Sep;13(9):2772-9.
9
[Phase II collaborative study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) for urological malignancies--Urological Co-operative THP Study Group].
Gan To Kagaku Ryoho. 1986 Feb;13(2):224-31.
10
Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.口服依托泊苷治疗不可切除的非小细胞肺癌。
Chemioterapia. 1984 Oct;3(5):324-6.
Zotero 插件